Individual prostate-specific antigen (PSA) forms as prostate tumor markers

Clinica Chimica Acta

Volumn 257, Issue 1, 1997, Pages 117-132

  Becker, Charlotte ^a   Lilja, Hans ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Human prostatic glandular kallikrein (hK 2); Prostate cancer; Prostate specific antigen; PSA

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TUMOR MARKER;

BLOOD ANALYSIS; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOASSAY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATE TUMOR;

HUMANS; ISOANTIGENS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031018110     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(96)06437-6     Document Type: Conference Paper

References (87)

1. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903.
2. Watt K, Lee P-J, M'Timkulu T, Chan W-P, Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
4. Lilja H, Abrahamsson P-A. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
5. Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl 1995;16:491-498.
6. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jpn J Legal Med 1971;25:322-324.
7. Graves H, Kamarei M, Stamey T. Identity of prostate specific antigen and the semen protein P30 purified by a rapid chromatography technique. J Urol 1990;144:1510-1515.
8. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 1973;24:134-144.
9. Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci 1978;23:106-115.
10. Riegman PH, Vlietstra RJ, van der Korput J, Romijn J, Trapman J. Characterization of the prostate-specific antigen gene. Biochem Biophys Res Commun 1989;159:95-102.
11. Riegman PH, Vlietstra RJ, Klaassen P, van der Korput J, Geurts van Kessel A, Romijn JTJ. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEES Lett 1989;247:123-126.
12. Riegman PH, Vlietstra RJ, Suurmeij L, Cleutjens CB, Trapman J. Characterization of the human kallikrein locus. Genomics 1992;14:6-11.
13. Lundwall Å, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-322.
14. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli E. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 1987;170:111-120.
15. Clements J. The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocrine Rev 1989;10:393-419.
16. MacDonald RJ, Margolius HS, Erdös EG. Molecular biology of tissue kallikrein. Biochem J 1988;253:313-321.
17. Chapdelaine P, Paradis G, Tremblay RR, Dubé JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-208.
18. Morris BJ. hGK-1: a kallikrein gene expressed in human prostate. Clin Exp Farm Phys 1989;16:345-351.
19. Young C-F, Montgomery BT, Andrews PE, Qiu S, Bilhatz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991;51:3748-3752.
20. Young C-F, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992;31:818-824.
21. Wolf DA, Schultz P, Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgens. Mol Endocrinol 1992;6:753-762.
22. Schedlich LJ, Bennetts B, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-437.
23. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41:54-58.
24. Yu H, Diamandis EP, Monne M, Croce CM. Oral-contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 1995;270:6615-6618.
25. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-1539.
26. Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995;41:204-210.
27. Pollen JJ, Dreilinger A. Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. Urology 1984;23:303-304.
28. Frazier HA, Humphrey PA, Burchette JL, Paulsson DE. Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992;147:246-248.
29. Diamandis EP, Yu H, Sutherland JA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-310.
30. Yu H, Diamandis E, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994;32:291-300.
31. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 1994;54:6344-6347.
32. Diamandis EP, Yu H. Editorial: New Biological Functions of Prostate-Specific Antigen. J Clin Endocrinol Metab 1995;80:1515-1517.
33. Schulz P, Stucka R, Feldmann H, Combriato G, Klobeck H-G, Fittler F. Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leading sequence. Nucleic Acids Res 1988;16:6226.
34. Bélanger A, van Halbeek H, Graves HCB, Grandbois K, Stamey TA, Huang L et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995;27:187-197.
35. Vihinen M. Modeling of prostate specific antigen and human glandular kallikrein. Biochem Biophys Res Commun 1994;204:1251-1256.
36. Villoutreix BO, Getzoff ED, Griffin J. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 1994;3:2033-2044.
37. Bridon DP, Dowell BL. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Urology 1995;45:801-806.
38. Villoutreix BO, Lilja H, Pettersson K, Lövgren T, Teleman O. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Protein Sci 1996;:836-851.
39. Papsidero LD, Wang MC, Valenzuela LA, Murphy GT, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980;40:2428-2432.
40. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981;2:89-96.
41. Kuriyama M, Wang MC, Lee C-I, Papsidero LD, Killian CS, Inaji H et al. Use of human prostate-specific antigen in monitoring prostate cancer patients. Cancer Res 1981;41:3874-3876.
42. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
43. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:1011-1017.
44. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987;138:1181-1184.
45. Oesterling JE, Chan DW, Epstein JL, Kimball AWJ, Bruzek DJ, Rock RC et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-772.
46. Armitage TG, Cooper EH, Newling DW, Robinson MR, Appleyard I. The value of measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 1988;62:584-589.
47. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-879.
48. Akiyama K, Nakamura T, Iwanaga S, Hara M. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein. FEBS Lett 1987;225:168-172.
49. Lilja H, Abrahamsson P-A, Lundwall Å. Semenogelin, the predominant protein in human semen. J Biol Chem 1989;264:1894-1900.
50. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-763.
51. Lilja H, Oldbring J, Rannevik G, Laurell C-B. Seminal-vesicle secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80:281-285.
52. Lee C, Keefer M, Zhao ZW et al. Demonstration of the roll of prostate-specific antigen in semen liquefaction by two-dimensional electrophoresis. J Androl 1989;10:432-438.
53. McGee R, Herr J. Human seminal vesicle-specific antigen is a substrate for prostate-specific antigen (or P-30). Biol Reprod 1988;39:499-510.
54. Lilja H, Laurell C-B. Liquefaction of coagulated human semen. Scand J Clin Lab Invest 1984;44:447-452.
55. McGee R, Herr J. Human seminal vesicle-specific antigen during semen liquefaction. Biol Reprod 1987;37:431-439.
56. Malm J, Hellman J, Magnusson H, Laurell C-B, Lilja H. Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem 1996;238:48-53.
57. Malm J, Hellman J, Lilja H. Characterization of the substrate specificity of prostate-specific antigen (PSA) by limited proteolysis of the major gel proteins in human semen. Scand J Clin Lab Invest 1995;55(Suppl.): 223, Abstract 544.
58. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RD. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;74:1046-1053.
59. Iwamura M, Hellman J, Cockett ATK, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHRP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996;48:317-325.
60. Iwamura M, di Sant'Agnese PA, Wu G et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724-1726.
61. Iwamura M, Abrahamsson P-A, Foss KA, Wu G, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675-679.
62. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192:940-947.
63. Powers JC, Harper JW. Inhibitors of serine proteinases. In: Barrett AJ, Salvesen G, eds. Proteinase inhibitors: Amsterdam: Elsevier, 1986;55-152.
64. Lilja H, Christensson A, Dahlén U et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 1991;37:618-625.
65. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220:45-53.
66. Carrell R, Travis J. alpha-1-antitrypsin and the serpins: variation and countervariation. Trends Biochem Sci 1985;10:20-24.
67. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989;264:11 539-11 542.
68. Leinonen J, Zhang W-M, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996;155:1099-1103.
69. Pettersson K, Piironen T, Seppälä M et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free and PSA-alpha-1-antichymotrypsin complex. Clin Chem 1995;41:1480-1488.
70. Laurell M, Christensson A, Abrahamsson P-A, Stenflo J, Lilja H. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J Clin Invest 1992;89:1094-1101.
71. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
72. Wood WG, Sloot van der E, Böhle A. The establishment and evaluation of luminescent-labelled immunometric assays for prostate-specific antigen-alpha-1-chymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991;29:787-794.
73. Heidtmann H-H, Havemann K. Assay of complexed alpha-1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1993;39:869-874.
74. Leinonen J, Lövgren T, Vornanen T, Stenman UH. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem 1993;39:2098-2103, ISSN 0009-9147.
75. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-1120.
76. Jacobsen SJ, Lilja H, Klee GG, Wright GL, Pettersson K, Oesterling JE. Comparability of the tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology 1994;44:512-518.
77. Lövgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K et al. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995;213:888-895.
78. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M-T, Cockett ATK et al. Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.
79. Piironen T, Lövgren J, Karp M, Eerola R, Dowell B, Lövgren T et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-1041.
80. Björk T, Abrahamsson P-A, Lilja H, Pettersson K, Cockett AK. Rates of clearance of free and complexed forms of PSA in serum after radical prostatectomy and transurethral microwave therapy. J Urol 1995;153:295A.
81. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
82. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community based population of healthy men. Establishment of age-specific reference ranges. J Am Med Assoc 1993;270:860.
83. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson P-A et al. Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-1095.
84. Bjartell A, Björk T, Matikainen M-T, Abrahamsson P-A, Di Santágnese A, Lilja H. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993;42:502-510.
85. Björk T, Bjartell A, Abrahamsson P-A, Hulkko S, Di Santágnese A, Lilja H. Alpha-1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994;43:427-434.
86. Björk T, Piironen T, Pettersson K et al. A comparison of the analysis of the different prostate-specific antigen forms in serum for the detection of clinically localized prostate cancer. Urology 1996;48:(in press).
87. Lilja H, Björk T, Abrahamsson P-A et al. Improved separation between normals, benign prostatic hyperplasia (BPH) and carcinoma of the prostate (CAP) by measuring free (F), complexed (C) and total (T) concentrations of prostate specific antigen. J Urol 1994;151:400A.